This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

27/100

✓ Peer-reviewed alzhub usefulness score 27 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Recent years have seen a large increase in research directed at AD immunotherapy. Among these, those on aducanumab, donanemab and lecanemab are particularly noteworthy. Lecanemab and aducanumab are already registered in the US, among others. More studies should be expected to try to solve the problems of qualifying patients into the appropriate groups or increasing the number of variables in ongoing trials. This will allow an even more reliable evaluation of the molecules under study and, consequently, further registrations of medicinal products.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Michalak, M., Kucharczyk, P., Parzęcka, K., Symulewicz, M., Domaradzki, O., Zań, W., et al. (2025). Advances in immunotherapy for Alzheimer's Disease 2020-2023 – a literature review. Journal of Education Health and Sport. https://doi.org/10.12775/jehs.2025.80.49304

Vancouver

Michalak M, Kucharczyk P, Parzęcka K, Symulewicz M, Domaradzki O, Zań W, et al. Advances in immunotherapy for Alzheimer's Disease 2020-2023 – a literature review. Journal of Education Health and Sport. 2025. doi:10.12775/jehs.2025.80.49304.

BibTeX

@article{michalak2025-aa1cc3c7,
  author  = {Michalak, Mateusz and Kucharczyk, Piotr and Parzęcka, Karolina and Symulewicz, Michał and Domaradzki, Olaf and Zań, Weronika and Kusy, Bartłomiej and Stolińska, Marta and others},
  title   = {{Advances in immunotherapy for Alzheimer's Disease 2020-2023 – a literature review}},
  journal = {Journal of Education Health and Sport},
  year    = {2025},
  doi     = {10.12775/jehs.2025.80.49304},
  url     = {https://doi.org/10.12775/jehs.2025.80.49304}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Recent years have seen a large increase in research directed at AD immunotherapy.
Among these, those on aducanumab, donanemab and lecanemab are particularly noteworthy.
Lecanemab and aducanumab are already registered in the US, among others.
More studies should be expected to try to solve the problems of qualifying patients into the appropriate groups or increasing the number of variables in ongoing trials.
This will allow an even more reliable evaluation of the molecules under study and, consequently, further registrations of medicinal products.

Why it matters

This literature review covers the large increase in Alzheimer's immunotherapy research from 2020 to 2023, noting that lecanemab and aducanumab are already registered in the US, among other places. It states that more studies are expected to solve problems of qualifying patients into appropriate groups and to allow more reliable evaluation of the molecules under study.

New to this subject? Start with our plain-English guide: Treatments →

Study details

Evidence strengthLow

How this study scored 27/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record and institution's track record, so those were left out: it earned 25 of the 93 points we could judge it on, which is 27 out of 100.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Journal of Education Health and Sport)
Journal's citation record	0 / 4	Journal of Education Health and Sport: journal h-index 16 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	0 / 7	Cited 0 times (OpenAlex, 2026-10-10)
Citations per year	0 / 5	0.0 citations a year over 3 year(s) since 2025
Impact for its field and year	0 / 6	Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	0 / 4	Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	— / 4	Senior author's record not available — left out of this score
Institution's track record	— / 3	No institution listed in OpenAlex — left out of this score
Multicenter collaboration	0 / 3	OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete)
Indexed in PubMed	1 / 2	Not in PubMed, but has a DOI
Free to read	2 / 2	Free to read
Points	25 / 93	Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 25 of the 93 points we could judge it on is 27 out of 100.
Total	27 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Treatments

Also in Treatments

190 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.

Similar studies

More on Treatments

See all studies in Treatments →